NeuroBo Pharmaceuticals Inc (NRBO)
2.53
-0.14
(-5.24%)
USD |
NASDAQ |
Nov 04, 16:00
2.88
+0.35
(+13.83%)
After-Hours: 06:39
NeuroBo Pharmaceuticals Total Liabilities (Quarterly): 9.809M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 9.809M |
March 31, 2024 | 6.942M |
December 31, 2023 | 6.096M |
September 30, 2023 | 4.875M |
June 30, 2023 | 3.983M |
March 31, 2023 | 10.98M |
December 31, 2022 | 11.78M |
September 30, 2022 | 1.619M |
June 30, 2022 | 1.249M |
March 31, 2022 | 1.533M |
December 31, 2021 | 2.202M |
September 30, 2021 | 1.952M |
June 30, 2021 | 1.241M |
March 31, 2021 | 1.009M |
December 31, 2020 | 3.765M |
September 30, 2020 | 3.692M |
June 30, 2020 | 3.214M |
March 31, 2020 | 3.795M |
Date | Value |
---|---|
December 31, 2019 | 2.176M |
September 30, 2019 | 3.073M |
June 30, 2019 | 2.05M |
March 31, 2019 | 1.712M |
December 31, 2018 | 17.11M |
September 30, 2018 | 14.02M |
June 30, 2018 | 13.76M |
March 31, 2018 | 14.02M |
December 31, 2017 | 15.08M |
September 30, 2017 | 16.26M |
June 30, 2017 | 5.274M |
March 31, 2017 | 4.545M |
December 31, 2016 | 4.122M |
September 30, 2016 | 1.936M |
June 30, 2016 | 22.68M |
March 31, 2016 | 2.252M |
December 31, 2015 | 16.87M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
1.009M
Minimum
Mar 2021
11.78M
Maximum
Dec 2022
4.311M
Average
3.692M
Median
Sep 2020
Total Liabilities (Quarterly) Benchmarks
Cytokinetics Inc | 1.415B |
Ocugen Inc | 23.62M |
enVVeno Medical Corp | 3.02M |
Scholar Rock Holding Corp | 93.24M |
Mirum Pharmaceuticals Inc | 431.77M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 28.75M |
Shareholders Equity (Quarterly) | 18.94M |